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The Runt family transcription factor CBFa2 (AML1, PEBP2aB, or Runx1) is required by hematopoietic stem cells and
expressed at high levels in T-lineage cells. In human T cells CBFa2 is usually transcribed from a different promoter (distal
promoter) than in myeloid cells (proximal promoter), but the developmental and functional significance of this promoter
switch has not been known. Here, we report that both coding and noncoding sequences of the distal 5* end are highly
conserved between the human and the murine genes, and the distal promoter is responsible for the overwhelming majority
of CBFa2 expression in murine hematopoietic stem cells as well as in T cells. Distal promoter activity is maintained
hroughout T cell development and at lower levels in B cell development, but downregulated in natural killer cell
evelopment. The distal N-terminal isoform binds to functionally important regulatory sites from known target genes with
wo- to threefold higher affinity than the proximal N-terminal isoform. Neither full-length isoform alters growth of a
yeloid cell line under nondifferentiating conditions, but the proximal isoform selectively delays mitotic arrest of the cell
ine under differentiating conditions, resulting in the generation of greater numbers of neutrophils. © 2000 Academic Press
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1INTRODUCTION
The transcription factor CBFa2, also known as PEBP2aB,
AML-1, or Runx1, is essential for all definitive hematopoi-
esis (Speck et al., 1999). A CBFa2 null mutation results in
the block of all definitive hematopoiesis and in embryonic
lethality associated with CNS hemorrhage by day 12.5
(Okuda et al., 1996; Wang et al., 1996). This phenotype,
locking definitive but not primitive hematopoiesis, is
imilar to the phenotype of the null mutation of other
ranscription factors implicated in hematopoiesis, such as
-myb (Mucenski et al., 1991) and PU.1 (Scott et al., 1994).
BFa2 probably acts upstream of c-myb and PU.1, since
BFa22/2 yolk sac, AGM, or fetal liver does not show c-myb
or PU.1 expression, whereas the same tissues in c-myb2/2
embryos do express CBFa2 (Okada et al., 1998). CBFa2 is
required for the formation of the definitive intraembryonic
1 E-mail: jtelfer@its.caltech.edu.
2 To whom correspondence should be addressed. Fax: (626) 449-756. E-mail: evroth@its.caltech.edu.
0012-1606/00 $35.00
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All rights of reproduction in any form reserved.ematopoietic stem cells in the aorta–gonad–mesonephros
egion, possibly acting as part of a developmental switch
etween endothelial and hematopoietic fates (Mukouyama
t al., 2000; North et al., 1999).
Among all other tissues, CBFa2 has been reported to be
xpressed at highest levels in T lineage cells, implying that
t has a special role there as well (Meyers et al., 1996; Satake
t al., 1995). CBFa2 binding sites are needed for transacti-
ation in the regulatory regions of important T cell genes,
uch as T-cell receptors a, b, g, and d and CD3e and d (Giese
et al., 1995; Hallberg et al., 1992; Hernandez-Munain and
rangel, 1994; Hsiang et al., 1993; Ogawa et al., 1993a;
Wang et al., 1993); IL-3 (Taylor et al., 1995; Uchida et al.,
1997); Granzyme B (Babichuk et al., 1996); granulocyte–
macrophage colony-stimulating factor (GM-CSF; Cockerill
et al., 1996; Takahashi et al., 1995); and RAG-1 (Brown et
al., 1997). CBFa2 can also play a key role in driving
xpression of the immunoglobulin m heavy chain enhancer,
hich is active in T cells as well as in B cells (Erman et al.,
998).
Although expressed at a lower level in normal myeloid
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364 Telfer and Rothenbergcells than in T cells, CBFa2 has numerous nonlymphoid
arget genes, such as M-CSF receptor (Zhang et al., 1994,
996), CD36 (Armesilla et al., 1996), neutrophil elastase,
nd myeloperoxidase (Nuchprayoon et al., 1994), and its
oles in regulating these have been relatively well studied.
his has left a mystery as to why much higher levels of
xpression might be required in T-lineage cells and whether
distinctive set of CBFa2 regulatory sequences might be
alled into play during T-lineage specification. Therefore, in
his work we examine the T-lineage and pluripotent hema-
opoietic precursor cells in the mouse system to character-
ze the forms of CBFa2 that play prominent developmental
roles in these cell types.
The function of CBFa2 is particularly dependent on the
tructural isoforms expressed because CBFa2 is not an
autonomous positive regulator, but a “context-dependent
coactivator” (Bruhn et al., 1997) that depends on interac-
tions with other proteins for its ability to activate its target
genes (Giese et al., 1995). The structure of the protein is
modular. CBFa2, like the products of the other gene family
members, CBFa1 (AML3, PEBP2aA, Runx2) and CBFa3
(AML2, PEBP2aC, Runx3), binds to DNA through a highly
onserved “Runt domain” (Berardi et al., 1999). The Runt
omain also mediates binding to the ubiquitously expressed
BFb subunit, which does not itself bind DNA but substan-
tially increases the DNA-binding activity of the complex
and is required for transactivation in some cis-regulatory
contexts (Gu et al., 2000; Kanno et al., 1998; Ogawa et al.,
993a; Wang et al., 1993). Other partner proteins interact
ith CBFa2 through separate domains outside the Runt
domain (Ahn et al., 1998; Bruhn et al., 1997; Gu et al., 2000;
Kim et al., 1999; McLarren et al., 2000; Petrovick et al.,
1998; Zhang et al., 1996). Various naturally occurring splice
isoforms of CBFa2 selectively retain or lose different inter-
ction domains (Bae et al., 1994; Levanon et al., 1996;
iyoshi et al., 1995). A shift to particular splice isoforms
ould favor or disfavor cooperation with particular cell-type
pecific factors. Indeed, several splicing isoforms are known
o have distinct activities on different target promoters
Meyers et al., 1995; Takahashi et al., 1995; Tanaka et al.,
1995; Uchida et al., 1997; Zhang et al., 1997). Thus the
mpact of CBFa2 expression on particular target genes
depends on the isoforms that are actually expressed in the
relevant cell type.
Another factor contributing to the impact of CBFa2 on
tem cells and lymphocytes may be quantitative. There is
vidence that some of its functions may depend on a high
hreshold of CBFa2 activity. For example, a null mutation
f the non-DNA-binding subunit CBFb eliminates defini-
ive hematopoiesis similar to a null mutation of the CBFa2
ene itself (Niki et al., 1997; Okuda et al., 1996). The
unction of the gene is highly sensitive to gene dosage, with
bnormalities of hematopoiesis appearing in cases of hap-
oinsufficiency (Barton and Nucifora, 2000). Also, although
BFa2 does not normally form homodimers, its activity is
xtremely susceptible to inhibition by various kinds of
ominant negative variants. The oncogenic translocation
Copyright © 2000 by Academic Press. All rightroteins of CBFa2 and CBFb seem to exert substantial
ominant negative effects in vitro (Hiebert et al., 1996;
eyers et al., 1995), and even in transgenic mice, heterozy-
gous transgenic “knock-in” mutants reproducing these fu-
sions give a phenotype close to that of a complete CBFa2
knockout (Castilla et al., 1996; Okuda et al., 1998; Yergeau
et al., 1997). A corollary of these arguments is that a
relatively modest increase in CBFa2 activity could be
associated with a qualitative gain of function in vivo.
In T cells, there has been evidence for some time from the
human system that a separate promoter can be used for
CBFa2 expression, one that is situated upstream of the
roximal promoter that controls CBFa2 expression in most
cells and tissues (Levanon et al., 1996; Miyoshi et al., 1995).
his distal 59 end has not been described in any murine
BFa2 forms, however. In addition, assays of the role of
uman AML1 in myeloid-associated gene expression have
ot reported any functional difference between forms en-
oded by mRNAs with the proximal or distal 59 ends. The
nown protein–protein interactions involving CBFa2 have
been mapped primarily or exclusively to the Runt domain
and C-terminal regions. Thus it has not been clear how use
of the distal 59 end would give T-cell-specific functional
effects.
In this paper, we investigate the forms of murine CBFa2
that are turned on at critical stages of hematopoiesis. We
show that murine hematopoietic stem cells as well as
differentiating thymocytes and mature T and B cells pref-
erentially use a distal 59 end for their CBFa2 expression and
that the bias toward expression of this distal promoter
correlates tightly with the developmental decision to adopt
a T- or B-cell, as opposed to a natural killer (NK) cell, fate.
The nucleotide and amino acid sequences encoded by the
murine distal 59 end are highly conserved, and we show that
the use of the “distal” N-terminus instead of the well-
characterized “proximal” N-terminus results in a CBFa2
protein that is functionally distinct, in both DNA binding
and impact on neutrophil differentiation.
MATERIALS AND METHODS
Library Screening and Plasmid Constructs
A C57BL/6 mouse spleen cDNA library in the Lambda ZAP II
vector (Stratagene, La Jolla, CA) was screened with 32P-labeled
BFa2 oligonucleotides (nucleotides 121–170 and 225–274) to
isolate a CBFa2 splenic clone encoding the entire open reading
frame. A CBFa2 random-primed probe derived from the CBFa2
plenic clone was used to isolate CBFa2 thymic clones by screening
C57BL/6 mouse thymus cDNA library in the Lambda ZAP
xpress/EcoRI vector (Stratagene). Positive clones were secondarily
creened for reactivity with a Runt domain random-primed probe
nucleotides 938–1688 of CBFa1) and confirmed by hybridization
ith 32P-end-labeled oligonucleotides from the CBFa2 runt domain
(nucleotides 393–317 and 677–707). Clones encoding the distal and
proximal 59 ends in pBK-CMV (Stratagene) were digested at the
SmaI site and religated to generate clones truncated at nucleotide
819 or amino acid 190. Full-length CBFa2 clones were generated by
s of reproduction in any form reserved.
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365Alternative Promoter for CBFa2 in Stem Cellsligating a SpeI–BstEII fragment encoding the distal or proximal 59
ends into a SpeI–BstEII-digested CBFa2 complete C-terminal clone
derived from a splenic Lambda ZAP II library (Stratagene).
To isolate CBFb, a SCID mouse thymocyte library in the
pSPORT plasmid (Gibco BRL; library constructed by Dr. Michele
Anderson) was hybridized with a 32P-end-labeled oligo from CBFb-
type 2 (nucleotides 589–628) (Ogawa et al., 1993a). cDNA clones
were sequenced by cycle sequencing with dye terminators (ABI,
California Institute of Technology DNA Sequencing Core Facility).
Cell Culture
EL4, ASL.1, R1.1, BW5147, WEHI-3, P388D1, A20, and BL3a
(Wong et al., 1994) (kindly provided by Dr. Peter Wong, Temple
University, Philadelphia, PA) were grown in RPMI 1640 supple-
mented with 10% FCS, 2 mM L-glutamine, and 100 mg/ml
penicillin–streptomycin (RPMI full medium). NFS-25 and NFS-70
were grown in Hybricare (ATCC) supplemented with 10% FCS and
100 mg/ml penicillin–streptomycin. FDCP-mix cells (clone A4),
nd FDCP-mix cells transduced with bcl-2 (clone 2J), were a kind
ift from Dr. Elaine Spooncer (Paterson Institute for Cancer Re-
earch, Manchester, UK) (Fairbairn et al., 1993). They were main-
ained in Fischer’s medium supplemented with 20% horse serum
nd 10% WEHI-3B conditioned supernatant. 32D clone 5 cells were
rown in RPMI full medium and 10% WEHI-3B conditioned
upernatant. This cell line shares many characteristics of pre-mast
ells and is distinct from the promyelocytic line 32DCl.3.
2Dcl.3 cells were obtained from the ATCC and maintained as
ecommended in growth medium: RPMI 1640 with 2 mM
L-glutamine adjusted to contain 1.6 g/L sodium bicarbonate, 4.5 g/L
glucose, 10 mM Hepes, and 1.0 mM sodium pyruvate, 80%; fetal
bovine serum 10%; WEHI-3B conditioned supernatant as a source
of IL-3 10%; and 50 mg/ml gentamycin. NIH/3T3 cells were
aintained in DMEM supplemented with 5% FCS, 2 mM
L-glutamine, and 100 mg/ml penicillin–streptomycin. Undifferenti-
ated ES cells (subline HM1, feeder-cell independent), kindly pro-
vided by Shirley Pease of the Caltech Transgenic Animal Facility,
were maintained in IMDM supplemented with 15% FCS, 1000
U/ml LIF (Gibco BRL, Gaithersburg, MD), 2 mM L-glutamine, 100
mg/ml penicillin–streptomycin, 1 mM sodium pyruvate, 0.1 mM
nonessential amino acids, and 0.1 mM b-mercaptoethanol on
gelatinized plates. EML-C1 cells (Tsai et al., 1994), kindly provided
by Dr. Schickwann Tsai, Fred Hutchinson Cancer Research Center
(Seattle, WA), were grown in IMDM supplemented with 20% donor
horse serum, 10% BHK-MKL (baby hamster kidney cells trans-
duced with mouse kit ligand) supernatant as a source of c-kit
ligand, 2 mM L-glutamine, and 100 mg/ml penicillin–streptomycin.
IL-2-activated NK cells were generated from C.B-17-SCID
plenocytes as described (Nandi et al., 1994). B6 SCID thymocytes
ere enriched for the absence of Sca-1 (Ly-6A/E) and heat-stable
ntigen (HSA; CD24) by staining with Sca-1-FITC and HSA-FITC,
ncubation with anti-FITC magnetic beads, and passage through a
ACS column (Miltenyi Biotec, Auburn, CA). Negatively selected
ells were treated as described (Nandi et al., 1994) with the addition
f 50 ng/ml IL-7 and 10% BHK-MKL supernatant as a source of
-kit ligand for 10 days. The resulting cells were uniformly positive
or the NK markers, NK1.1 and CD16 (FcgRII/III), and negative for
D3e (Pharmingen, San Diego, CA).
Flow Cytometry
Thymocytes from C.B-17-SCID mice (Taconic Labs) werestained with antibodies against HSA conjugated to phycoerythrin, p
Copyright © 2000 by Academic Press. All rightDX5-FITC, and Sca-1-biotin (Pharmingen). The Sca-1-biotin was
then visualized by incubation with streptavidin-Red670 (Gibco
BRL). The stained thymocytes were analyzed and sorted on a
Coulter Epics Elite flow cytometer (Coulter Electronics, Hialeah,
FL) as previously described (Diamond et al., 1997; Wang et al.,
1998).
Fetal liver cells from B6 Ly5.1 (day 13) and B6 3 DBA/2 F1 (day
13.5) were depleted of erythrocytes by incubation with anti-
Ter119-biotin and streptavidin magnetic beads and passage over a
MACS column (Miltenyi Biotec). The remaining cells were stained
with anti-c-kit (CD117)-FITC, anti-Sca-1-PE, and biotinylated anti-
B220, anti-CD3, anti-CD4, anti-CD8, anti-NK1.1, anti-Gr-1, and
anti-IL-7R. To isolate hematopoietic stem cells (Morrison et al.,
1995), the cells were incubated with streptavidin-Red 670, ana-
lyzed, and sorted for c-kit and Sca-1 positivity and lineage marker
negativity on a Coulter Epics Elite flow cytometer (Coulter Elec-
tronics).
RT-PCR
RNA was extracted with acid phenol–4 M guanidinium isothio-
cyanate (Chomczynski and Sacchi, 1987). Five micrograms of
RNA; 250 ng of random hexamer; 50 mM Tris–HCl, pH 8.3; 75 mM
KCl; 3 mM MgCl2; 10 mM DTT; 1 mM each dATP, dGTP, dCTP,
dTTP; and 10 units of RNase-free DNase (Boehringer Mannheim,
Roche Diagnostics) were incubated at 37°C for 30 min, then at
75°C for 5 min. Two hundred units of Superscript II (Gibco BRL)
was added and the reaction mixture was incubated at 25°C for 10
min, 42°C for 50 min, and 70°C for 15 min. Two units of RNase H
(Gibco BRL) were added and the reaction was incubated at 37°C for
20 min. One microliter of the cDNA was used for each PCR.
The PCR primers were as follows: AAACAACCACAGAA-
CCACAAGTTG (distal 59), CAAAAATGCTGTCTGAAGC-
ATCGTTTCC (distal 59 reverse), TCAAAGCGAGGCTCTGTT-
GGCATTTG (exon 3 UTR-proximal 59), CGCATCACAA-
AAGCCGATTGAGTAAGGA (exon 3-proximal 59 reverse),
CGTCCCGGATGGCACTGTGGTCACC (exon 4), GTTGAG-
AGCGCGGCGCCGGTGGATGCGTT (exon 8 reverse), AAT-
CAACGGCACAGTCAAGGCCGAGAATG (GAPDH 204), and
CGGCACGTCAGATCCACGACGGAC (GAPDH 759 rev).
PCRs were run with 0.2 U of Taq Gold (Perkin–Elmer Applied
iosystems, Foster City, CA), 1.5 mM MgCl2, 10 pmol of each
primer, 0.2 mM dNTP, and 0.5 mCi of [a-32P]dCTP per reaction in
a final volume of 25 ml. Cycling conditions were as follows: 94°C
or 8 min, then two-step cycling between 94 and 63°C for 1 min
ach, with a final incubation at 72°C for 10 min. Samples were
esolved on a 2% agarose gel, blotted in 0.4 M NaOH onto Hybond
1 (Amersham Pharmacia Biotech, Piscataway, NJ), and quanti-
ed by phosphorimaging (Molecular Dynamics, Sunnyvale, CA).
Northern Dot Blot Hybridization
Distal and proximal 59 end CBFa2 PCR products were generated
ith distal 59/distal 59 reverse and exon 3 UTR-proximal 59/exon
-proximal 59 reverse primers (see above for sequences). Purified
CR products were used as templates for random-primed labeling
ith [a-32P]dATP and [a-32P]dCTP using the Prime-a-Gene kit
(Promega, Madison, WI). Probes were purified on Elu-Tip (Schlei-
cher & Schuell, Keene, NH) and counted. A murine poly(A)1 RNA
ot blot normalized to eight housekeeping genes (Master Blot;
lontech Laboratories, Palo Alto, CA) was hybridized in Ex-
ressHyb buffer (Clontech), according to instructions. The distal 59
s of reproduction in any form reserved.
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366 Telfer and Rothenbergend probe had a specific activity of 5 3 108 cpm/mg; the proximal 59
end probe had a specific activity of 1.6 3 109 cpm/mg. Dot blots
hybridized with the distal 59 probe were exposed three times longer
than blots hybridized with the proximal 59 probe.
Electrophoretic Mobility Shift Assay
The following pairs of oligonucleotides were annealed and gel
purified to generate a double-stranded DNA fragment: TcRbE2-1
TAGCACAACAGGATGTGGTTTGACATTTA and TcRbE2-2
CTAGTAAATGTCAAACCACATCCTGTTGTG, TcRbE3-1 GAT-
CCGGATGCGGTGAGTGTGGTTCTCATG and TcRbE3-2
GATCCATGAGAACCACACTCACCGCATCCGG, TcRa-1
GATCCTCTCCCGCAGAAGCCACATCCTCTG and TcRa-2
GATCCAGAGGATGTGGCTTCTGCGGGAGAG, MPO-1 CTA-
GACTGACCATTAACCACAACCAGTTG and MPO-2 TAG-
CAACTGGTTGTGGTTAATGGTCAGT, and RAG-1.1 GATC-
TATCATCATCTGTGGTTAGCCGTCTG and RAG-1.2
GATCCAGACGGCTAACCACAGATGATGATA. The double-
stranded DNA fragments were labeled by Klenow-mediated fill-in
reaction. They were purified on an Elu-Tip (S&S) and counted.
Proteins used in EMSA reactions were generated using the TNT
in vitro transcription/translation system, as directed (Promega). For
each reaction, 1 mg of cDNA template was added. Proteins were
equalized by translation in the presence of [35S]methionine (Trans-
abel; ICN Radiochemicals, Costa Mesa, CA), resolution on SDS–
AGE, and quantitation by phosphorimaging. Differing numbers of
ethionines were corrected for and the proteins were made
quimolar by dilution in the transcription/translation mixture.
MSA reactions were carried out in a final volume of 20 ml, with
0.1 mg/ml BSA, 50 mM KCl, 70 mM NaCl, 10 mM Tris, pH 7.5, 1
mM DTT, 0.5 mM EDTA, 10% glycerol, 10 mg poly(dI-dC)–poly(dI-
C), 2 ml in vitro-translated CBFa2 proteins, 1 ml in vitro-translated
BFb, and 50,000 cpm DNA probe. Samples were incubated for 30
min at 4°C before 2 ml of loading buffer (20% glycerol, 1 mg/ml
bromophenol blue, and 1 mg/ml xylene cyanol) was added. Samples
were loaded on a 12% acrylamide (29 acrylamide:1 bis) 0.333 TBE
gel, prerun for 1.5 h at 20 mA, constant voltage, and resolved at 300
V. Bands were quantified by scanning the exposed film into Adobe
PhotoShop. A mean channel value was determined for a 48-pixel
rectangle within the band. The channel values were corrected for
background and converted to counts per minute by comparison to
a standard curve taken from a scan of an autoradiogram exposed by
a dot blot of serially diluted [a-32P]dCTP, 3000 Ci/mmol.
Antiserum mobility shift EMSAs were done as described above,
xcept 1 ml of antiserum was preincubated with the mixture for 10
in at room temperature before the DNA probe was added and the
ixture incubated at 4°C for 30 min. Antiserum mobility shift
MSAs with nuclear extract were done by substituting 5 mg of
nuclear extract prepared as previously described (Tugores et al.,
1992) for the in vitro-translated CBFa2 and CBFb, decreasing the
amount of poly(dI-dC)–poly(dI-dC) to 0.5 mg, and running the
reactions on a 7% polyacrylamide gel.
Antiserum Generation
The CBFa2 distal N-terminal 19-amino-acid polypeptide
MASDSIFESFPSYPQCFMR), covalently linked to keyhole limpet
emocyanin (California Institute of Technology, Protein/Peptide
icro Analytical Laboratory), was injected subcutaneously into
ew Zealand White rabbits. Antiserum against the human AML1CBFa2) N-terminal peptide (RIPVDASTSRRFTPPS), cross-reactive
Copyright © 2000 by Academic Press. All rightwith murine CBFa2 (Meyers et al., 1993, 1995), was generously
rovided by Dr. Scott W. Hiebert (Vanderbilt University). This
eptide was taken from a proximal N-terminal AML1; however, all
ut four of the amino acids (RIPV) are shared by the distal
-terminal AML1B.
32Dcl.3 Retroviral Transduction and
Differentiation Assay
Full-length CBFa2 cDNAs with the proximal and distal 59 ends
were generated by PCR from cDNA templates and cloned into the
BglII–XhoI sites of the bicistronic retroviral vector, pMIG, into
which we had inserted sequences encoding the HA epitope tag
(YPYDVPDYA) and a stop codon at the XhoI–EcoRI sites, forming
a C-terminal fusion protein. pMIG is a mouse stem cell virus
(MSCV) derivative (Van Parijs et al., 1999), which was kindly
provided by Dr. Luk van Parijs. Transduced cells in which this
vector is actively expressed can be identified by their expression of
enhanced green fluorescent protein (E-GFP) from the same RNA
transcript as the inserted CBFa2 genes. The retroviral vectors were
ackaged in ecotropic coats by transient transfection of FNX
Phoenix-Eco) cells, kindly provided by Dr. Garry Nolan, and the
esulting supernatants were used to infect cultures of 32Dcl.3 cells
rowing in IL-3-supplemented medium. Cells were sorted for
-GFP expression and grown as a bulk population or cloned by
imiting dilution. Clones were chosen for differentiation assays by
atching E-GFP expression levels as determined by FACS. For
ifferentiation assays, cells were washed twice in PBS and plated in
00 ml differentiation medium (same as growth medium described
above, except no IL-3) containing 500 U/ml human G-CSF (Bio-
source International, Camarillo, CA) at 1 3 105 cells per well of a
6-well plate. Cell counts were taken by harvesting 1 well per time
oint. Cells were cytospun onto positively charged slides and
tained by May–Grunwald–Giemsa. For Western blotting of ex-
racts, transduced cells were lysed in 20 ml RIPA buffer (50 mM
ris–HCl, pH 7.4, 150 mM NaCl, 0.05% SDS, 1% deoxycholic acid,
% Triton X-100, 13 complete protease inhibitors (Boehringer
annheim)) per 1 3 106 cells at 4°C for 30 min. Samples were
entrifuged at 15,000 rcf for 15 min, and the supernatants were
ssayed for protein content. One hundred micrograms of protein
er lane was fractionated by SDS–PAGE and transferred to PVDF
embrane, blocked in 2% milk/TBS overnight, and probed with
A probe (Y-11; Santa Cruz Biotechnology), and anti-rabbit-HRP
Santa Cruz Biotechnology), followed by development with Lumi-
ol Reagent (Santa Cruz Biotechnology) and exposure to film.
RESULTS
Preferential Use of an Alternative 5* End
by CBFa2 cDNAs from Thymus
To determine the structures of the CBFa subunits ex-
ressed during T cell development, a thymocyte cDNA
ibrary was screened for CBFa2 clones. The majority of
CBFa2 clones from this library (Fig. 1) use a 59 end that is
istinct from the reported 59 end of murine CBFa2 (Bae et
al., 1993; Wang et al., 1993). This distinctive 59 end is
highly homologous to one previously reported in the hu-
man system which is known to be expressed from a distal
promoter, as discussed below. We will refer to the previ-
ously reported murine 59 end as the proximal 59 end and to
s of reproduction in any form reserved.
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367Alternative Promoter for CBFa2 in Stem Cellsthe new 59 end as the distal 59 end. Of 12 nonduplicated
unt domain-positive CBFa2 cDNAs that we cloned from a
hymus library (9 unique sequences), 9 utilized the distal 59
FIG. 1. CBFa2 cDNAs derived from a murine thymus library. Str
oundaries and regions known to encode distinct functional doma
999), ear-2 (Ahn et al., 1998), C/EBP, PU.1 (Petrovick et al., 199
ndicated. The negative regulatory DNA binding domain (NRDB) (K
ranslocation points are indicated by vertical arrows (Erickson et a
995). Horizontal arrows indicate the locations of the primers use
BFa2 sequences have been previously reported as GenBank Acce
not correspond to previously reported sequence are indicated as nov
intron between exons 6 and 7. A preponderance of distal 59 end usag
n addition, three of the nine distal 59 clones display alternative spli
f these alternatively spliced species, D5 and D6, can be detected in
acids at which these C-termini are truncated are indicated.nd (6 unique sequences), 2 were truncated such that the 59 s
Copyright © 2000 by Academic Press. All rightnd cannot be determined, and only 1 utilized the proximal
9 end.
These thymic cDNA clones also presented evidence for
res of cDNAs are diagrammed with respect to known intron/exon
otential interaction sites in the C-terminus with Ets (Kim et al.,
LY (Bruhn et al., 1997), and Groucho (Aronson et al., 1997) are
et al., 1998) C-terminal to the Runt domain is marked. Oncogenic
92; Golub et al., 1995; Nucifora et al., 1993, 1994; Romana et al.,
amplify the distal and proximal 59 ends and exons 4 to 8. Murine
Nos. D13802 and D26532; the sequences of these clones that do
he clone truncated at amino acid 241 appears to have an unspliced
een, with nine distal 59 clones compared to one proximal 59 clone.
o novel sequences, predicted to result in truncated C-termini. Two
ocyte mRNA (J.C.T. and E.V.R., unpublished results). The aminouctu
ins. P
8), A
anno
l., 19
d to
ssion
el. T
e is s
cing t
thymeveral novel splicing patterns in the body of the mRNA
s of reproduction in any form reserved.
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368 Telfer and Rothenbergmessage (Fig. 1, D5, D6.5, D8, and D6). In vivo utilization of
the new D5 and D6 splicing patterns was confirmed by
RT-PCR analysis (data not shown). A characterization of
the regulation and function of distinct 39 spliced isoforms
will be the subject of a separate report.
FIG. 2. Conserved sequence of the CBFa2 distal 59 ends. (A) The c
o the human genomic sequence (Accession Nos. HS229043 and AF
cDNA clone were used to PCR-amplify a fragment from T cell line
Exons 1 and 2 correspond to sequence from CBFa2 distal 59 end cD
Identities are indicated by asterisks. The translational start site an
nucleotide sequence. Consensus DNA binding sites for CBFa2 (acca
DDBJ under Accession No. AF193030. (B) Comparison of the CBF
uman (hu), and chicken (ch) species. Human AML1c (GenBank Ac
N-terminus, but has an additional exon encoding 13 amino acids, sh
form of CBFa1 (Accession No. D14636); til-1 (Accession No. AF00
utilizes a downstream translation initiation codon similar to that
J238394) is reported to have an alternative promoter and N-term
ember of the CBFa family cloned from chicken (Accession No. Z3
N-terminus. The first five amino acids of the proximal N-termini o
CBFa3 (Accession No. AF155880) are identical. These are replacedThe genomic clone of the distal 59 end was cloned from a d
Copyright © 2000 by Academic Press. All rightnique PCR product from exon 1 through exon 2 (Fig. 2A).
here is a striking degree of identity between the human
nd the murine genomic sequences—94% in exon 1, includ-
ng a perfect match for the first 46 bp of 59 untranslated
egion, and 89% in exon 2. The intron also shows a high
arison of the genomic sequence of the murine CBFa2 distal 59 end
62) shows a high degree of identity. Primers derived from a CBFa2
genomic DNA, which was subsequently subcloned and sequenced.
clones. Exon 1 and exon 2 are in boldface; intron 1 is in lightface.
amino acids encoding the distal N-terminus are noted below the
e underlined. These sequences are available from EMBL/GenBank/
stal N-terminus (m-dis.59) to related N-termini from murine (m),
on No. D43969) displays 100% identity to the murine CBFa2 distal
in the gap. Osf2 (Accession No. AF010284) is an osteoblast-specific
) is a CBFa1 gene product produced by retroviral insertion which
by the CBFa2 distal N-terminus. Human CBFa3 (Accession No.
however, its splice acceptor site has not been reported. The only
) utilizes an N-terminus similar to that of the murine CBFa2 distal
Fa2 (Accession No. D13802), CBFa1 (Accession No. D14636), and
he distal N-termini in CBFa2 and CBFa1 and probably in CBFa3.omp
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369Alternative Promoter for CBFa2 in Stem Cellssequences encode 59 untranslated region, suggesting that
the uncommonly strong selective pressure for conservation
of these sequences is derived from transcription factor
binding sites or favorable effects on translational efficiency.
The distal 59 ends of both human and murine CBFa2
nclude a translational start site, such that CBFa2 proteins
translated from these mRNAs have an N-terminal sequence
different from those encoded by mRNAs with proximal 59
ends. The murine distal 59 end codes for 19 amino acids (Fig.
2B), rather than the 32 amino acids coded for by the human
distal 59 end of AML1B, AML1c, or AML1g (Levanon et al.,
1996; Meyers et al., 1995; Miyoshi et al., 1995). The
additional amino acids in the human distal N-terminus are
FIG. 3. Expression of CBFa2 from proximal and distal promoters i
f (A) CBFa2 proximal 59 end (upper band) versus CBFa2 distal 59
xon 6 in the transcript, middle band indicates absence of exon 6, a
ere quantitated by phosphorimaging as described under Materials
he results were used to calculate the (D) ratios of distal 59 end to
–8 to GAPDH. The primers and amplification conditions used he
roximal 59 end products (data not shown). Results shown are repencoded by a separate, intermediate exon, located only ;6 f
Copyright © 2000 by Academic Press. All rightkb upstream of the proximal promoter but ;150 kb down-
stream of the distal promoter (see Accession No. D43969 vs
AP001721). This intermediate exon is evidently spliced into
the human distal mRNA but omitted from the murine
mRNA. However, both murine and human distal 59 ends
are then spliced into exon 3 to lead into the same sequence,
replacing 5 amino acids at the proximal N-terminus. The
first 19 amino acids of the distal N-terminus are identical
between mouse and human and 63% identical between
mouse CBFa2, the “distal” N-terminus of human CBFa3,
nd the only Runt family member isolated from chicken
Fig. 2B). The distal N-terminus of CBFa2 is even 37%
dentical to the “distal” N-terminus of its fellow Runt
phoid and nonlymphoid cell types. RT-PCR analysis of expression
lower band), (B) CBFa2 exons 4–8 (top band indicates presence of
ttom band’s identity is unknown), and (C) GAPDH. Product yields
ethods. Background was subtracted from the values obtained and
DH and proximal 59 end to GAPDH and (E) ratio of CBFa2 exons
plified distal 59 end products less efficiently on a molar basis than
tative of three experiments.n lym
end (
nd bo
and M
GAP
re amamily member Osf2, an osteoblast form of CBFa1 (Ducy et
s of reproduction in any form reserved.
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370 Telfer and Rothenbergal., 1997), or til-1, the same gene inappropriately expressed
in thymus via retroviral insertion (Stewart et al., 1997).
This high degree of conservation at the protein and nucle-
otide levels suggests that both the structure and the regu-
lation of the distal N-terminus are functionally significant.
Tissue Specificity of Distal Promoter Usage
The circumstantial evidence indicating that the regula-
tion of the distal promoter is evolutionarily conserved made
it important to determine the developmental context(s) in
which it is active. In limited studies in the human system,
the use of the distal promoter has been associated with T
cells and also found in malignantly transformed acute
myelogenous leukemia cells, but the relationship of this
regulation to normal hematopoiesis has not been explored.
We therefore used RT-PCR and hybridization to normalized
dot blots of poly(A)1 RNA to analyze expression systemati-
cally in different tissues and cell types. Our analysis of the
murine system revealed only three developmental compart-
ments in which the distal promoter is significantly ex-
pressed: T cells, immature hematopoietic precursors, and to
a lesser extent B cells.
RT-PCR analysis of multiple murine tissues and cell
lines showed that CBFa2 expression from the distal pro-
oter is universal in immature and mature T cells and T
ell lines, but reduced in myeloid cell lines and nonhema-
opoietic cells. Figure 3 shows a representative analysis, in
hich expression of full-length CBFa2 with either pro-
moter was detected by amplification of exons 4–8 (Fig. 3B)
and the relative expression of mRNAs with the two pro-
moters (Fig. 3A) was detected by primers specific for the
distal (Fig. 3A, lower band) and proximal 59 ends (upper
band). Expression of CBFa2 generally was stronger in hema-
opoietic cell types (lanes 1–5, 7–19) than in most nonhe-
atopoietic cells (lanes 6, 20–29), as determined by ampli-
cation of the sequences from exons 4–8 encompassing the
unt domain (Fig. 3B). But as a fraction of total CBFa2
RNA, transcripts initiating with the distal promoter (Fig.
3A, lower band) were most predominant in immature
T-lineage cells in the thymus (lanes 1 and 2). Distal 59 end
transcripts were also seen in almost all T cell tissue culture
lines tested (lanes 8–11), whereas the CBFa2 expressed in
myeloid and multilineage myeloid progenitor cell lines
made less use of the distal promoter (lanes 16–19). How-
ever, the distal promoter was clearly active in some hema-
topoietic non-T cells: it contributed a substantial fraction of
the CBFa2 mRNAs in B cell lines representing various
developmental stages and in tissues enriched for immature
hematopoietic cells, such as SCID bone marrow and fetal
liver (Fig. 3, lanes 3, 4, and 7). In contrast, little if any
expression from the distal promoter was detected in non-
hematopoietic tissues, regardless of whether they express
low or high levels of CBFa2 overall (Fig. 3, lanes 20–29).
This general pattern of expression was confirmed by
hybridization of probes specific for each of the two CBFa2
9 ends to a prenormalized, commercial dot blot of poly(A)
Copyright © 2000 by Academic Press. All rightNA from multiple mouse tissues (Fig. 4). This analysis
onfirmed that the preferential expression of the distal
romoter is highly specific for lymphocytes, among the
issues assayed. Although the levels of hybridization with
ach probe that represent equal numbers of molecules were
ot determined here, it is clear that the two tissues in
hich mRNA with the distal 59 end predominates are
hymus and spleen, i.e., the two tissues most dominated by
mmature and mature lymphocytes, respectively (Fig. 4,
anes 1 and 2). In all other tissues analyzed, the proximal
romoter is expressed at similar or higher levels.
The tissue specificity of promoter utilization is especially
triking because this was the only structural variation of
BFa2 mRNA that seemed clearly regulated. In an exon-
y-exon analysis using RT-PCR, we were unable to find
omparable evidence that internal splicing isoforms of the
BFa2 mRNA were differentially utilized in different tis-
ues (J.C.T. and E.V.R., data not shown). Thus, although
here is strong biochemical evidence that CBFa2 isoforms
with different functions can be generated by splicing out
exons that encode particular C-terminal domains, it is the
promoter variations that appear to be subject to evident
developmental control in vivo.
Predominant Utilization of the Distal Promoter
in Stem Cells
Expression of the distal promoter in lymphocytes could
be induced as a specific part of the lymphocyte developmen-
FIG. 4. Confirmation of RT-PCR expression data with RNA dot
blot normalized to eight housekeeping genes. The murine poly(A)1
RNA dot blot (Masterblot; Clontech) was hybridized with probes
specific for CBFa2 distal and proximal 59. Data are graphed as
percentages of the total signal with each probe. The samples are: (1)
thymus, (2) spleen, (3) brain, (4) eye, (5) liver, (6) lung, (7) kidney, (8)
heart, (9) skeletal muscle, (10) smooth muscle, (11) pancreas, (12)
thyroid, (13) submaxillary gland, (14) testis, (15) ovary, (16) pros-
tate, (17) epididymus, (18) uterus, (19) embryo—7 days, (20)
embryo—11 days, (21) embryo—15 days, (22) embryo—17 days.tal program, or it could be inherited from the hematopoietic
s of reproduction in any form reserved.
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371Alternative Promoter for CBFa2 in Stem Cellsstem cells from which lymphocytes differentiate. The pres-
ence of some distal promoter transcripts in tissues rich in
immature hematopoietic cells (Fig. 3, lanes 3, 4, and 7)
raised the question of which CBFa2 promoter is active in
stem cells themselves.
Figure 5 shows that definitive-type hematopoietic stem
cells purified from fetal liver by fluorescence-activated cell
sorting (Morrison et al., 1995) express very high levels of
CBFa2 mRNA and that in these cells the overwhelming
ajority of these mRNAs initiate with the distal promoter.
n a direct comparison with thymocytes and splenocytes
Figs. 5A–5D, lanes 3–5), two independent preparations of
tem cells (Figs. 5A–5D, lanes 1 and 2) expressed higher
verall levels of CBFa2 (Fig. 5D) and made even higher
FIG. 5. CBFa2 usage in fetal liver hematopoietic stem cells an
proximal 59 end and distal 59 end CBFa2 mRNA and (B) GAPD
independent preparations are shown (lanes 1 and 2), compared w
wild-type spleen (lane 5), lung (lane 6), and the hematopoietic stem
Bands were quantified as described for Fig. 3. (C) The ratio of distal
(D) The ratio of distal 59 PCR product to GAPDH and proximal 59 P
hematopoietic stem cells, with corresponding lane numbers in A–D
the CBFa2 distal 59 and proximal 59 fragments. PCRs were spiked
o exposure to film (F) or a phosphorimaging screen, from which the
Molecular Dynamics). (G) The results were graphed as signal versu
or the distal 59 (dis) and proximal 59 (prox) ends results in an equal
he 20-fold difference in moles of distal 59 (thy-dis) and proximalroportional use of the distal promoter (Fig. 5C) than t
Copyright © 2000 by Academic Press. All rightmmature T-cell precursors (Fig. 5A–5D, lane 3). This
roperty of stem cells ex vivo is not completely shared by
hree cell lines that can terminally differentiate into ery-
hroid and myeloid cells (Figs. 5A–5D, lanes 7–9). These cell
ines express less CBFa2 overall and make substantially
higher relative use of the proximal promoter than the ex
vivo fetal liver stem cells. However, primary multipotent
hematopoietic stem cells represent the cell type with the
most prolific and the most selective expression of distal
CBFa2 transcripts of all.
Calibration experiments (Figs. 5E and 5F) allowed us to
onvert the RT-PCR signals to known copy numbers of
roximal or distal 59 end sequences. Under these condi-
ions, the molar ratio of promoter usage in normal, unfrac-
ripotent hematopoietic stem cell lines. RT-PCR analysis of (A)
RNA in FACS-sorted subsets of hematopoietic stem cells. Two
RAG-22/2 thymus (lane 3), wild-type C57BL/6 thymus (lane 4),
l lines EML-C1 (lane 7), BL3a (lane 8), and FDCP-mix A4 (lane 9).
R product to proximal 59 PCR product was graphed on a log scale.
roduct to GAPDH. (E) Schematic of T and B cell development from
icated. (F and G) Calibration of PCRs using primer sets amplifying
0.5 mCi [a-32P]dCTP, resolved on an agarose gel, and blotted prior
l 59 (200 bp, Dis) and proximal (300 bp, Prox) bands were quantified
les of template showing that an equal number of moles of template
l of signal. Results shown are representative of three experiments.
y-prox) mRNA messages in the thymus is indicated by arrows.d plu
H m
ith
cel
59 PC
CR p
ind
with
dista
s mo
leveionated thymocytes could be shown to be about 20:1
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372 Telfer and Rothenbergdistal:proximal, in reasonable agreement with the yield of
cDNA clones of each type in our initial screen (cf. Fig. 1).
The results in Fig. 5C then imply that about 50–100 times
more CBFa2 RNA is derived from the distal promoter than
from the proximal promoter in definitive hematopoietic
stem cells. The form of CBFa2 that is essential for stem cell
development and survival is thus most likely to be the form
with the “distal” N-terminus.
Developmentally Regulated Utilization of the Two
CBFa2 Promoters in Developing Lymphocytes:
ivergence between T and Natural Killer
ell Lineages
These results raised the question of the developmental
FIG. 6. Regulation of CBFa2 promoter usage in early lymphoid dif
(A) proximal 59 end and distal 59 end and (B) GAPDH in the fo
thymocytes enriched in the Sca-12HSA2 population and expanded i
to grow out NK cells (lane 7); splenic B220-positive B cells (lane 8);
SCID bone marrow, in which the B-cell precursors are arrested at an
from SCID bone marrow (lane 11). Bands were quantified as describ
Development schematic of cellular populations from (A). Lane nu
to proximal 59 PCR product was graphed on a log scale. (E) The rat
GAPDH.relationship between the distal promoter expression in
Copyright © 2000 by Academic Press. All righttem cells and in T-lineage cells. We used a fine dissection
f immature lymphocyte development to address this ques-
ion. Multiple lymphoid surface markers with well-studied
xpression profiles are available so that fluorescence-
ctivated cell sorting can be used to dissect precursor and
roduct subsets from virtually any phase of the lymphocyte
evelopmental program (Anderson et al., 1999; Rothenberg
et al., 1999).
In early T cell development before TCR gene rearrange-
ment, uncommitted precursors are segregated to distinct
fates at a succession of regulatory branch points. One of the
last developmental alternatives these cell give up during
T-lineage commitment is the ability to give rise to NK cells
(Ikawa et al., 1999; Michie et al., 2000; Sanchez et al., 1994)
as shown in Fig. 6C. To determine whether T-lineage
tiation diverges between T and NK cell types. RT-PCR analysis of
ng: FACS-sorted subsets of SCID thymocytes (lanes 1–5); SCID
2 to grow out NK cells (lane 6); SCID splenocytes expanded in IL-2
-type bone marrow, mostly myeloid and B cell precursors (lane 9);
y stage (lane 10); and FACS-sorted immature CD19-positive B cells
r Fig. 3. Results shown are representative of three experiments. (C)
s are indicated inside cells. (D) The ratio of distal 59 PCR product
distal 59 PCR product to GAPDH and proximal 59 PCR product toferen
llowi
n IL-
wild
earl
ed fo
mber
io ofspecification and commitment events have an impact on
s of reproduction in any form reserved.
i
t
t
s
z
a
t
T
“
2
s
G
6
i
m
m
p
t
d
t
t
1
A
a
r
o
r
s
f
c
N
s
f
p
p
t
a
d
5
(
m
p
l
D
373Alternative Promoter for CBFa2 in Stem CellsCBFa2 regulation, we isolated precursor subsets represent-
ng cells at these branch points, as well as populations of
heir mature descendants of different types, and analyzed
heir utilization of the distal and proximal promoters, as
hown in Fig. 6. The results show separate promoter utili-
ation programs that distinguish developing T cells, B cells,
nd NK cells.
The key event in the early T cell development program is
he specification of pluripotent precursors to undertake
-lineage differentiation, a step that occurs between stages
1” and “2” in Fig. 6. Like stem cells (cf. Fig. 5, lanes 1 and
vs lane 3), the precursors that have not yet undergone
pecification (lane 1) express more CBFa2 in relation to
APDH than do the T-lineage-specified cells (lane 2) (Figs.
A, 6B, and 6E). However, both utilize the distal promoter
n preference to the proximal promoter (Fig. 6D), as do the
uch more advanced thymocyte populations of normal
ice (cf. Fig. 5, lane 4). Preferential use of the distal
romoter is therefore established from the earliest stages of
FIG. 7. Specific antiserum against the distal CBFa2 N terminus
Definition of antiserum specificity. An antiserum mobility shift as
translation product (amino acids 1–190) and a CBFa2 distal 59 in vi
ntiserum was used to show baseline levels of binding to a RAG pr
istal and the proximal 59 in vitro translation products and inhibits
9 form (a-dis) blocks only binding by the distal 59 in vitro translati
lane 6). CBFb-containing complexes are indicated by the top aster
Expression of distal N-terminal CBFa2 protein with DNA-bindin
obility shift assay was carried out with nuclear extracts from thy
WEHI-3B (lanes 9–12). Nuclear proteins from these cells were inc
reimmune antiserum (odd-numbered lanes) or an antiserum speci
anes). A supershifted complex present only in the thymocyte sam
NA protein complexes that are depleted by antibody supershiftinhe T-lineage pathway. u
Copyright © 2000 by Academic Press. All rightIn contrast to the T cell lineage, cells taking other
evelopmental pathways show a sharply reduced activity of
he distal promoter. The SCID thymus also harbors imma-
ure cells (c-kit1) taking the NK pathway (Diamond et al.,
997; Wang et al., 1998) (J.C.T., unpublished data) (Fig. 6C).
lthough these cells share many effector genes with T cells,
nd appear to differ mainly in their lack of TCR gene
earrangements, they display a sharply reduced expression
f distal 59 end transcripts (Fig. 6, lanes 3–5), especially
elative to proximal 59 end transcripts. NK cells can be
electively maintained in culture and activated to acquire a
ull effector phenotype in response to high doses of the
ytokine interleukin-2 (IL-2). When either the immature
K-like cells from the thymus or mature NK cells from the
pleen are cultured with IL-2 (Fig. 6, lanes 6 and 7), they
urther extinguish expression from the distal promoter,
referentially maintaining expression from the proximal
romoter (Figs. 6D and 6E, lanes 6 and 7). Assuming that
he thymic NK-like cells are ultimately derived from the
tes DNA binding in vitro and in thymocyte nuclear extracts. (A)
as carried out with equal amounts of CBFa2 proximal 59 in vitro
ranslation product (distal 59 19 1 6–190 amino acids). Preimmune
lanes 1, 3, 5, and 7). An anti-AML1 antiserum recognizes both the
ng by both (lanes 2 and 8), while an antiserum specific for the distal
roduct (lane 4) and not the proximal 59 in vitro translation product
he lower asterisk indicates complexes containing only CBFa2. (B)
ivity in thymocytes, but not in myeloid cell lines. An antiserum
ytes (lanes 1–4) and the myeloid cell lines P388D1 (lanes 5–8) and
d with MPO and TCRbE2 32P-labeled oligonucleotide probes and
y recognizing the CBFa2 distal N-terminus (a-dis, even-numbered
incubated with the anti-dis antiserum is indicated with an arrow.
indicated by an asterisk.deple
say w
tro t
obe (
bindi
on p
isk; t
g act
moc
ubate
ficall
ples
g arencommitted precursors represented in population 1, there
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374 Telfer and RothenbergFIG. 8. Preferential DNA binding by CBFa2 protein with the distal N-terminus. Electrophoretic mobility shift assays were carried out
using (A) RAG-1 probe, (B) TcRbE2 probe, and (C and D) MPO probe. (A, B, C) A proximal 59 CBFa2 in vitro translation product (amino acids
–190) was compared to a distal 59 CBFa2 in vitro translation product (distal 59 19 1 6–190 amino acids). Five amounts (2, 1, 0.5, 0.25, and
.1 ml) of equalized CBFa2 in vitro translation products were used per reaction, as indicated. (D) A full-length CBFa2 proximal 59 in vitrotranslation product (lane 31, amino acids 1–451) was compared to a CBFa2 distal 59 in vitro translation product (lane 32, distal 59 19 1 6–451
Copyright © 2000 by Academic Press. All rights of reproduction in any form reserved.
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375Alternative Promoter for CBFa2 in Stem Cellsis a 203 drop in distal promoter utilization relative to
proximal promoter utilization (i.e., 100.4–(20.9) 5 101.3 5 19.95)
in the course of NK differentiation and in vitro maturation.
Thus the NK differentiation program diverges sharply from
the T cell differentiation program in its progressive shut-
down of the distal CBFa2 promoter.
B cells are less closely related to T cells than NK cells, but
still share distinctive lymphoid gene expression features. A
role for CBFa2 has recently been demonstrated in the
xpression of immunoglobulin genes by B cells (Erman et
l., 1998). Immature B-lineage cells (Fig. 6, lane 11) express
BFa2 from both promoters, albeit at lower levels than any
mmature T cells. This expression pattern resembles that of
otal bone marrow cells (Fig. 6, lanes 9 and 10) and fetal
iver cells (cf. Fig. 3, lanes 3 and 4), suggesting that it may be
haracteristic of other immature hematopoietic cell types.
s B cells mature, though, a pattern more resembling that
f T cells is established (Fig. 6, lane 8). Thus, taking the
ematopoietic stem cell expression pattern as a starting
oint, distal CBFa2 promoter usage remains strong
throughout T cell development, declines with NK cell
maturation, and appears to be transiently reduced and then
restored in B cell development.
Lymphocyte development includes a number of obliga-
tory checkpoints at which cells are permitted to survive
only if they can undergo a form of activation in response to
an environmental signal. To determine whether the differ-
ences in distal promoter activity could be attributed to
common lymphocyte activation pathways, splenocytes
from normal mice (;55% mature B cells and ;30% mature
T cells) were stimulated with increasing amounts of Ca1
ionophore in the presence of the phorbol ester PMA, stan-
dard agents for inducing effector functions and prolifera-
tion, to activate the protein kinase C and Ras pathways.
After 6 h, the amounts of distal and proximal CBFa2 mRNA
ere determined. These results showed that the distal
romoter was not induced or repressed by stimulation, but
here was strong, specific induction of the proximal pro-
oter (data not shown). Thus the differences in distal
romoter activity in various stages of lymphocyte develop-
ent are unlikely to be short-term responses to stimula-
ion, but rather appear to be controlled by developmental
tatus.
amino acids) and to products truncated at amino acid 190 (lanes
asterisks; the lower asterisks indicates complexes containing only C
products of CBFa2 alone. (E) The amount of CBFa2 isoform DNA
ensitometry and graphed as the ratio of distal to proximal DNA b
(RAG-1; columns 2, 5, and 8), and M (MPO; columns 3, 6, and 9). S
same experiment are summed in columns 1–3 and graphed sepa
represent the means of the ratios of binding by distal N-terminal
individual data points. The numbers of data points per column (n
column 7, n 5 8; column 9, n 5 12; column 1, SE 5 0.27; column
1.7; column 6, SE 5 0.7; column 7, SE 5 0.2; column 8, SE 5 1.1; an
y SDS–PAGE. The constructs used to program the lysates are dista
istal 59 (lane 3) and proximal 59 (lane 4) full-length CBFa2, and CBFb
Copyright © 2000 by Academic Press. All rightFunctional Differences between CBFa2 Proteins
ncoded from the Distal and Proximal Promoters:
NA Binding Affinity
The results presented thus far show that the two promot-
ers of CBFa2 are differential targets of developmental regu-
lation. The proteins they encode are also functionally
different, as shown by the following evidence that they can
mediate distinct effector roles in their regulation of down-
stream genes.
The expression of mRNA with the distal 59 end does
result in accumulation of CBFa2 protein with the predicted
-terminus. This can be detected with a new “a-dis”
antiserum, the specificity of which is shown in Fig. 7A. In
electrophoretic mobility shift assays, the a-dis antiserum
locks DNA binding by in vitro translation products from
DNA templates with the distal 59 end, but not binding by
roducts from cDNA templates with the proximal 59 end
Fig. 7A, compare lanes 4 and 6). A control antiserum with
eactivity against the common region predicted for the two
roducts (a-AML1) can partially inhibit binding by both
(Fig. 7A, lanes 2 and 8). The a-dis antiserum shows the same
pecificity in the immunoprecipitation of [35S]methionine-
abeled in vitro translation products, although it does not
ecognize denatured proteins in Western blotting (data not
hown). When nuclear extracts from thymocytes and my-
loid cell lines are used in DNA binding assays instead of in
itro translation products, the a-dis antiserum inhibits
binding and/or generates supershifted complexes in thymus
samples but not in the myeloid samples (Fig. 7B, lanes 2 and
4 vs lanes 6, 8, 10, and 12). Thus, the a-dis antiserum
emonstrates that the preferential expression of CBFa2
RNA with the distal 59 end in thymocytes results in
rotein with the distal N-terminus making a substantial
ontribution to the CBFa2 pool.
Direct binding studies demonstrate that CBFa2 isoforms
with the distal N-terminus show higher binding activities
for CBFa2 target sites than equivalent isoforms with the
proximal N-terminus. Representative data are shown in
Figs. 8A–8D, with a summary of the data from multiple
assays in Fig. 8E. An in vitro transcription/translation
ystem was used to generate products from matched cDNA
onstructs as shown in Fig. 8F, and the incorporation of
nd 34). Complexes containing CBFb are indicated by the upper
2. This was determined by running EMSA with in vitro translation
ing shown in (A–C) and in other experiments was determined by
g. The probes are indicated as T (TCRbE2; columns 1, 4, and 7), R
s from complexes containing CBFb and those lacking CBFb in the
y in columns 4–6 and columns 7–9, respectively. The columns
s to binding by proximal N-terminal forms; the squares are the
standard errors of the mean (SE) are, columns 1–6 and 8, n 5 5;
5 0.8; column 3, SE 5 0.78; column 4, SE 5 0.9; column 5, SE 5
lumn 9, SE 5 1. (F) 35S-labeled in vitro-translated proteins resolved
ane 1) and proximal 59 (lane 2) CBFa2 truncated at amino acid 190,33 a
BFa
bind
indin
ignal
ratel
form
) and
2, SE
d co
l 59 (l
(lane 5).
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w376 Telfer and Rothenberg[35S]methionine label was used together with the known
number of methionines to determine equal molar amounts
of the in vitro translation products to be used for binding
activity comparisons. For most of these studies, cDNA
constructs were used that generated products with en-
hanced DNA binding activity (prox 1–190 and dis 19 1
6–190), by deletion of an internal inhibitory domain down-
FIG. 9. Distinct functional activities of distal and proximal CBFa
of myelocyte terminal differentiation to polymorphonuclear neutr
tiated in the presence of G-CSF. The majority of cells transduced wi
(yellow asterisks) or polymorphonuclear neutrophils (red asterisks)
are still dividing (note mitotic figures indicated by purple arrowh
asterisks). Greater than 90% of the surviving cells are terminall
differentiating conditions after transduction with proximal isoform
ith a matched, stable level of E-GFP expression (C), the proxim
differentiating conditions while the distal isoform or the contro
experiments.stream of the Runt domain (Gu et al., 2000; Kanno et al.,
Copyright © 2000 by Academic Press. All right1998). As shown in Fig. 8D, the binding activities of the
corresponding full-length proteins were much weaker (as-
terisks in lanes 31 and 32; cf. asterisks in lanes 33 and 34).
For full-length as well as truncated CBFa2 proteins, how-
ever, the distal N-terminal form bound more strongly than
the proximal form (Figs. 8A–8D). The effect was most
pronounced with either the TCRbE2 or the RAG-1 target
orms in growth and differentiation of 32Dcl.3 cells. (A) Schematic
. (B) May–Grunwald–Giemsa staining of transduced cells differen-
GFP alone or with the distal isoform of CBFa2 are postmitotic band
ay 4, while those transduced with the proximal isoform of CBFa2
, proximal, day 4) or in a myelocyte nuclear configuration (green
ferentiated by day 8. (C) Survival curves of cells cultured under
Fa2, distal isoform of CBFa2, or control E-GFP alone. In subclones
oform of CBFa2 promotes enhanced neutrophil generation under
es not. This experiment is representative of three independent2 isof
ophil
th E-
by d
eads
y dif
of CB
al is
l dosite, with the distal N-terminal form yielding approxi-
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377Alternative Promoter for CBFa2 in Stem Cellsmately 33 more complex than the proximal N-terminal
form.
Formation of a ternary complex with CBFb is known to
enhance the DNA binding affinity of CBFa2, but the
difference did not correlate with an increased ability to
recruit CBFb in this case. As summarized in Fig. 8E, the
nhanced DNA binding due to the use of the distal
-terminus was seen equally in complexes with and with-
ut CBFb.
Functional Differences between Distal and
Proximal N-terminal Forms of CBFa2 during
rowth and Differentiation of a Myeloid Cell Line
To test whether the structural differences between the
two N-terminal forms could affect growth and development
in a hematopoietic context, we took advantage of the
32Dcl.3 myeloid progenitor cell line. 32Dcl.3 cells can grow
continuously in response to IL-3 or arrest division and
differentiate in vitro into neutrophils in response to granu-
locyte colony-stimulating factor, and they have been used
extensively to document effects of different C-terminal
isoforms and translocation products of the CBFa2 gene
Dann et al., 2000; Tanaka et al., 1995; Zhang et al., 1997).
The distal and proximal CBFa2 mRNA expression profile of
32Dcl.3 cells resembles that of other cell lines capable of
terminally differentiating into myeloid cells (Fig. 5, lanes 7,
8, and 9 and data not shown).
Full-length CBFa2 coding regions with the proximal and
distal 59 ends were incorporated into a retroviral vector and
transduced into 32Dcl.3 cells to establish a series of stably
expressing subclones. The retroviral vector, based on a
MSCV backbone, includes an E-GFP reporter expressed
from an internal ribosome entry site, enabling the monitor-
ing of transcription of the bicistronic message in transduced
cells. The CBFa2 coding sequences were also fused in-frame
ith an epitope tag to permit monitoring of the CBFa2
rotein. Epitope-tagged proteins of the expected sizes were
etectable at low levels in transductants with both distal
nd proximal 59 end constructs (data not shown). The stably
ransduced clones encoding both forms of CBFa2 grew well
in IL-3-containing growth medium and maintained levels of
E-GFP expression similar to those expressed by control
transductants with E-GFP only.
The effects of the two isoforms diverged, however, when
the transductants were induced to undergo neutrophilic
differentiation. Control cells and cells transduced with the
distal isoform of CBFa2 stopped dividing and terminally
ifferentiated, undergoing the dramatic nuclear condensa-
ion and segmentation that are typical of this differentia-
ion program (Fig. 9A). Viable cells in the cultures were
60% converted to nonmitotic band and hypersegmented
olymorphonuclear neutrophils by day 4 (Fig. 9B, GFP and
istal). They then died (Fig. 9C), leaving only a few remain-
ng neutrophils by day 8. In contrast, cells transduced with
he proximal 59 end isoform displayed a delay in the onset of
erminal differentiation induced by G-CSF (Fig. 9C). At day C
Copyright © 2000 by Academic Press. All right, control GFP-, distal-, and proximal-transduced cell popu-
ations had all upregulated expression of cell-surface CD11b
Mac-1) and myeloperoxidase mRNA (data not shown),
uggesting that these markers are an earlier indication of
ranulocytic differentiation than nuclear condensation and
egmentation. However, at day 4, many of the proximal-
ransduced cells were still dividing (purple arrowheads in
ig. 9B), and 96% displayed an undifferentiated myelocytic
uclear morphology. Shortly after the day 4 time point, the
ajority of the cells infected with proximal CBFa2 isoform
topped dividing (Fig. 9C) and .90% of the cells became
olymorphonuclear neutrophils by day 8 (Fig. 9B, proximal).
he effect of this delay in terminal differentiation was to
ncrease by over 10-fold the total number of terminally
ifferentiated neutrophils harvested on day 8.
This effect was not simply an abnormality of the clones
tably transformed with the proximal CBFa2 construct
because it was also seen in bulk-transduced populations
(data not shown). E-GFP expression as monitored by FACS
remained stable throughout the differentiation period (data
not shown). Preliminary results in other in vitro differen-
tiation systems also show that the distal isoform, as well as
the proximal isoform, is active (J.C.T. and E.V.R., unpub-
lished data). These results demonstrate that the distal
isoform and the proximal isoform of CBFa2 are functionally
different. They diverge in their abilities to support myelo-
cyte growth and survival under conditions of differentia-
tion, despite the small difference in their amino acid
composition.
DISCUSSION
CBFa2 has been known for some time to be expressed in
profuse variety of mRNAs, with two different promoters
s well as a multitude of 39 splicing isoforms. This paper
resents the first evidence for the fine-scale developmental
ignificance of the alternative promoter usage and the first
vidence for functional differences between the protein
roducts of the two 59 end isoforms. We confirm that the
istal promoter is more highly expressed than the proximal
n developing T cells, but show that this preference is
robably inherited from the stem cell population and not
nduced de novo in committed T cells. We also show that
hile developing T and B cells continue to use this pro-
oter, differentiation along the natural killer cell pathway
s accompanied by a sharp repression of transcription from
he distal promoter. The extraordinarily high sequence
onservation of this distal transcript provides circumstan-
ial evidence that both the regulatory sequences enforcing
his pattern of expression and the distally encoded
-terminus of the protein have been highly selected in
volution. The use of the distal as opposed to the proximal
romoter results in a protein that has enhanced DNA-
inding activity on sites in the regulatory elements of
everal target genes. Despite its high DNA-binding activity,
BFa2 with the distal N-terminus is also functionally
s of reproduction in any form reserved.
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378 Telfer and Rothenbergdistinguished by a failure to enhance neutrophil production
under conditions under which the proximal N-terminal
form is stimulatory. Differential promoter usage thus af-
fects both the regulation and the regulatory impact of
CBFa2 expression.
The strong conservation of the distal promoter and
-terminal coding sequence is indicative of an evolution-
rily selected biological function for this domain of the
rotein. The mouse–human conservation at the DNA level
s even more striking. Particularly highly conserved are
ong stretches of noncoding region at the extreme 59 ends of
he mRNAs (101/105 bp identical). An intron contains one
0-bp block of perfect sequence identity. These conserved
equence blocks seem most likely to represent extended
rotein–DNA interaction sites that are required for correct
xpression. Although regulatory sites are usually found
pstream of the 59 cap sites of RNAs and not in transcribed
egions, this rule is frequently violated in the case of genes
ike CBFa2, which use TATA-less promoters. Among the
equences that are perfectly conserved, there are two con-
ensus CBFa2 binding sites in tandem in the first 20 bp of
he distal 59 end, with a third conserved site at 196 (Fig. 2),
upporting an earlier proposal that CBFa2 can regulate its
wn expression from the distal promoter (Ghozi et al.,
996). Additional factors, though, are likely to be at least as
mportant. The exceptionally rigid conservation of such a
arge extent of noncoding sequences implies that there is
trong selective pressure to maintain the regulation of this
romoter by an extensive set of protein–DNA interactions.
Hematopoietic stem cell (HSC)-enriched populations
verwhelmingly prefer to drive CBFa2 expression from the
istal promoter. Therefore it is the distal N-terminal form
hat is normally used for the critical role of CBFa2 in the
eneration and maintenance of definitive HSC (Mukou-
ama et al., 2000; North et al., 1999; Okada et al., 1996,
1998; Tracey et al., 1998; Wang et al., 1996; Yergeau et al.,
997). Definitive HSC arise within the embryo and repre-
ent a separate cell type, possibly a separate lineage, from
rimitive stem cells that arise in the yolk sac. The defini-
ive HSC are distinguished genetically by their complete
ependence on c-myb and c-kit as well as on CBFa2
(Dzierzak et al., 1998). In these cells, CBFa2 is also essential
for maintenance of its own expression (North et al., 1999).
This implies that definitive hematopoiesis may depend on
the positive feedback regulatory loop involving the distal
promoter, with the development of HSC from hemangio-
blasts being regulated by distal 59 CBFa2 binding to CBFa2
sites in the distal 59 promoter and stimulating transcription
of the distal 59 message.
This need not be the only context in which CBFa2
autoregulation is used. Use of the same factor at more than
one developmental choice point is seen in multiple systems
(Sieweke and Graf, 1998). The transcription factor c-myb
also acts on two points in hematopoietic development: the
development of myeloid precursors from HSCs and the
development of T and B cells from lymphoid progenitors
(Allen et al., 1999). Thus, the shared preservation of maxi-
Copyright © 2000 by Academic Press. All rightmal levels of distal 59 CBFa2 activity throughout T cell
ifferentiation might indicate that the same positive feed-
ack loop helps generate T cells from HSC. However, the
xpression of CBFa2 from the distal promoter in T cells,
nd to a lesser extent in B cells, can be contrasted with the
elective shutoff of this promoter in NK cells. NK cells are
lose relatives of T cells that share much of their gene
xpression program with T cells (Wang et al., 1998) and can
ontinue to be generated by bipotent T/NK cell precursors
s the last developmental alternative until T-lineage com-
itment (Ikawa et al., 1999; Michie et al., 2000; Plum et
l., 1999). Since the distal promoter is expressed in T cells,
cells, and pluripotent precursors, its downregulation in
K cells represents a novel, NK-lineage-specific disconti-
uity.
The choice of promoters influences the function of the
rotein encoded by the CBFa2 gene. First, the distal
N-terminal isoforms of CBFa2 consistently bind the RAG-1
and TCRb target sites approximately threefold better than
he proximal, irrespective of the particular C-terminal iso-
orm used and irrespective of the presence of the cofactor
BFb. The basis of this enhanced DNA-binding affinity
emains to be determined, but it is worth noting that a
omologous N-terminal sequence of the CBFa family mem-
ber Osf2/CBFa1/til-1 (Fig. 2B) has an enhancing effect on
transactivation of similar magnitude (Thirunavukkarasu et
al., 1998). The addition of 19 amino acids to an N-terminus
separate from the DNA-binding Runt domain could en-
hance DNA binding directly or counteract one of the
intramolecular binding-inhibitory domains known to be
present in the CBFa2 molecule (Gu et al., 2000; Kanno et
al., 1998; Kim et al., 1999). However it works, such an
nhancement of DNA binding could be significant for an
ctivity that is so sensitive to gene dosage (Barton and
ucifora, 2000).
Second, despite its superior DNA-binding activity, the
istal N-terminal isoform is less effective than the proximal
-terminal form in the context of neutrophil terminal
ifferentiation. It is striking that the proximal isoform
elays mitotic arrest and cell death, generating a superior
eutrophil yield, while the distal isoform, normally used in
ong-lived cell types, does not. Preliminary studies show
hat the distal isoform can have stronger activities than the
roximal in other differentiation systems (J.C.T. and E.V.R.,
npublished data). Thus, this result is reminiscent of other
vidence that the growth control activities of transcription
actors are tightly linked to particular developmental pro-
rams in hematopoietic cells (Chiang and Monroe, 1999;
erlov and Graf, 1998; Seshasayee et al., 1998). There is
lso precedent for functional differences between the prod-
cts encoded by dual promoters in the case of Osf2/CBFa1/
il-1, which is required for the maturation of osteoblasts
nd subsequent bone formation (Komori et al., 1997; Otto
t al., 1997). While a proximal N-terminal form is broadly
xpressed (Ogawa et al., 1993b), the two forms of CBFa1
that are known to have clear functions use the distal
N-terminus, i.e., both the osteoblast-specific form, Osf2
s of reproduction in any form reserved.
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379Alternative Promoter for CBFa2 in Stem Cells(Ducy et al., 1997), and the abnormal, lymphomagenic form
il-1 (Stewart et al., 1997) (Fig. 2B). Transfection of embry-
nic fibroblasts with the different CBFa1 isoforms shows a
division of labor, with different isoforms best able to
transcriptionally activate disparate promoter/enhancers of
osteoblast marker genes (Harada et al., 1999). In the case of
CBFa2, it remains to be determined which are the most
mportant target genes that are differentially regulated by
istal and proximal N-terminal forms. Our results suggest,
owever, that genes used in undifferentiated stem cells may
e among the preferred positive targets of the distal
-terminal form.
As a proto-oncogene and an essential factor for stem cell
evelopment, CBFa2 is intimately involved in growth
and/or survival of cells. It is noteworthy that NK lympho-
cytes are distinguished from stem cells, T cells, and B cells
by their limited proliferative life span. T, B, and stem cells
are capable not only of extensive growth, but also of resting
in G0 for long periods of time in between activation events
ithout losing the capacity to resume proliferation. Little is
nown about the mechanisms through which different cell
ypes are brought under such different behavioral con-
traints. The precise developmental regulation and evolu-
ionary conservation of the two promoters of CBFa2 offer a
ew tool to probe the divergent programs of survival and
roliferation adopted by these hematopoietic cells.
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